


AMENDMENTS TO THE CLAIMS

 55. (Currently Amended) A method of ~~treating apnea or apnea disorders~~ ^{apnea} in a patient which comprises administering to said patient in need of ~~such~~ said treatment a therapeutically effective amount of (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (-) stereoisomer.

56. (Original) The method of claim 55, wherein the apnea being treated comprises central apnea, deglutition apnea, obstructive apnea, sleep apnea, or sleep induced apnea.

57. (Original) The method of claim 55, wherein the patient is a human.

58. (Original) The method of claim 55, wherein (+) norcisapride is administered orally.

59. (Original) The method of claim 58, wherein (+) norcisapride is administered as a tablet or a capsule.


60. (Original) The method of claim 55, wherein the amount administered is from about 0.5 mg to about 500 mg.

61. (Original) The method of claim 60, wherein the amount administered is from about 1 mg to about 250 mg.

62. (Original) The method of claim 55, wherein (+) norcisapride is administered together with a pharmaceutically acceptable carrier.

63. (Original) The method of claim 58, wherein said (+) norcisapride is administered from one to four times per day.

64. (Original) The method of claim 55, wherein (+) norcisapride is administered parenterally, transdermally, rectally or sublingually.

 71. (Currently Amended) A method of ~~preventing or managing apnea or apnea disorders~~ in a patient which comprises administering to said patient in need of ~~such~~ said prevention or management a therapeutically effective amount of (+)-norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (-) stereoisomer.